Wonkyung Moon

Wonkyung Moon

Auto-generated profile, based on publicly available information

Wonkyung Moon

National Agency for Korean Medicine Innovative Technologies Development, National Institute for Korean Medicine Development, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2023 in Integrative Medicine Research
Verified
Journal Article
Open access
SSSeungwon Shin
Seungwon Shin
WMWonkyung Moon
Wonkyung Moon
SKSuran Kim
Suran Kim
SCSeok Hee Chung
Seok Hee Chung
JKJong-Woo Kim
Jong-Woo Kim
MPMINJUNG PARK
MINJUNG PARK
Since evidence-based medicine has been pursued in complementary and alternative medicine, the clinical practice guideline (CPG) has become a key factor in providing standardized and validated practices in Korean Medicine (KM). We aimed to review the current status and characteristics of the development, dissemination, and implementation of KM-CPGs. We searched KM-CPGs and relevant publication via web-based databases. We organized the searching results focused on the year of publications and the development programs to show which and how KM-CPGs have been development. We also reviewed the manuals for KM-CPG development to introduce concise characteristics of the KM-CPGs published in Korea. The KM-CPGs have been developed according to manuals and standard templates for developing evidence-based KM-CPGs. First, CPG developers reviews the previously published CPGs for a clinical condition of interest and plans the CPG development. After finalizing the key clinical questions, the evidence is searched, selected, appraised, and analyzed following the internationally standardized methods. The quality of the KM-CPGs is controlled by a tri-step appraisal process. Second, the CPGs were submitted for the appraisal of the KM-CPG Review and Evaluation Committee. The committee evaluates the CPGs according to the AGREE II tool. Finally, the Steering Committee of the KoMIT project reviews the entire process of developing the CPGs and confirms it for public disclosure and dissemination. Evidence-based KM from research to practice can be achieved with the attention and effort of multidisciplinary entities such as clinicians, practitioners, researchers, and policymakers for the CPGs.

30 June 2023 in Journal of Pharmacopuncture
Verified
Journal Article
Open access
PDF file
Chan-Young KwonChan-Young Kwon
Chan-Young Kwon
SSSeungwon Shin
Seungwon Shin
OKO-Jin Kwon
O-Jin Kwon
WMWonkyung Moon
Wonkyung Moon
NKNamKwen Kim
NamKwen Kim
MPMINJUNG PARK
MINJUNG PARK
Chan-Young Kwon, Seungwon Shin, O-Jin Kwon, Wonkyung Moon, Namkwen Kim, Minjung Park. J Pharmacopuncture 2023;26:198-209. https://doi.org/10.3831/KPI.2023.26.2.198

3 June 2022 in Integrative Medicine Research
Verified
Journal Article
Open access
Chan-Young KwonChan-Young Kwon
Chan-Young Kwon
SSSeungwon Shin
Seungwon Shin
BLBoram Lee
Boram Lee
JSJong Cheol Seo
Jong Cheol Seo
JNJeong-Hyun Nam
Jeong-Hyun Nam
MPMINJUNG PARK
MINJUNG PARK

26 November 2025 in Integrative Medicine Research
Verified
Journal Article
Open access
YKYongJoo Kim
YongJoo Kim
NYNan-He Yoon
Nan-He Yoon
SJSoobin Jang
Soobin Jang
KBKyeore Bae
Kyeore Bae
WMWonkyung Moon
Wonkyung Moon
SKSujin Kim
Sujin Kim
Herbal medicine decoctions (HMD) are potential treatments for Bell’s palsy (BP), but real-world evidence regarding the safety is limited. This study investigated whether HMD use for BP was associated with risk of adverse events using a nationwide claims-based database in South Korea. This retrospective cohort study used data from the Korean Health Insurance Review and Assessment database. We applied coarsened exact matching, through which 1627 BP patients who received at least one HMD prescription between November 2020 and February 2022 were matched with 1627 BP patients who did not use HMD. Difference-in-differences logistic regression modeling compared the incidences of safety outcomes between HMD users and non-users. No significant differences were observed in the risk of hepatotoxicity, renal failure, allergic events, hospitalization, and emergency department visits between HMD users and non-users with BP, assessed at 3, 6, 9 and 11 months after HMD prescription. All effect estimates and corresponding 95 % confidence intervals included the null value. There was no significant difference in the risk of safety outcomes between HMD users and non-users with BP. Further research is warranted to understand the safety of specific herbal formulas or individual herbs using broader safety measures.